Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Gannett’s $1.04 Billion Term Loan Facility
Cravath represented Gannett Co., Inc. in the transaction. Gannett Co., Inc. executed its $1.04 billion term loan facility. The transaction closed on February 9, 2021. Gannett Co., Inc.,...